8-K: Tvardi Therapeutics Updates on STAT3 Inhibitors, Clinical Progress

Tvardi Therapeutics provided an updated corporate presentation detailing progress on its STAT3 inhibitor programs, TTI-101 and TTI-109, across idiopathic pulmonary fibrosis and hepatocellular carcinoma, with key data readouts anticipated in the first half of 2026.

Summary

• An updated corporate presentation was made available on January 16, 2026, detailing the company's pipeline and clinical progress.
• The company focuses on targeting STAT3, a central mediator in fibrosis-driven diseases, with product candidates TTI-101 and TTI-109.
• Preliminary conclusions from the REVERTIPF Phase 2 trial for TTI-101 in Idiopathic Pulmonary Fibrosis (IPF) were released in October 2025, with additional data reported in January 2026.
• Topline data from the REVERTLiver Cancer Phase 1b/2 trial for TTI-101 in Hepatocellular Carcinoma (HCC) is expected in the first half of 2026.
• Phase 1 healthy volunteer data for TTI-109, a prodrug designed to enhance TTI-101 delivery and tolerability, is also expected in the first half of 2026.
• Cash, cash equivalents, and short-term investments totaled $36.5 million as of September 30, 2025.
• The anticipated cash runway is expected to fund the company's operating plan into the fourth quarter of 2026.

Sentiment

Score: 7

Explanation: The filing presents a balanced view with challenges in the IPF trial but strong, encouraging interim data in HCC and a promising new prodrug (TTI-109). The upcoming data catalysts in 1H 2026 are significant, and the cash runway into Q4 2026 provides stability for these milestones. The overall sentiment leans positive due to the potential in HCC and the strategic development of TTI-109, despite the IPF trial's complexities.

Positives

• TTI-101-treated patients in the REVERTIPF Phase 2 study demonstrated a greater decline in fibrosis score (approximately 9% vs. 2% for placebo) from baseline to 12 weeks in a post hoc analysis.
• TTI-101-treated patients showed a greater decline in IL-6, a key pro-inflammatory cytokine, compared to placebo, with a 4.5-fold difference in slope.
• 63% of TTI-101-treated patients demonstrated an increase in Forced Vital Capacity (FVC) at 12 weeks, and less of a decline when compared to the REVERT and historical placebo groups.
• TTI-101 monotherapy in the Phase 1 HCC trial led to durable partial responses in fibrotic tumors, with one patient achieving a 49% reduction in sum of targets over 10 months and another a 66% reduction over 14 months.
• TTI-101 demonstrated enhanced biological activity in fibrotic cancers with an Objective Response Rate (ORR) that exceeds the current expected standard of care in 2L HCC (less than 5%).
• REVERTLiver Cancer interim Phase 1b/2 data shows promising Disease Control Rates (DCR) and ORRs across monotherapy (Cohort A: 67% DCR, 33% ORR) and combination with atezolizumab/bevacizumab (Cohort C: 50% DCR, 33% ORR).
• TTI-109, a prodrug of TTI-101, showed no toxicology findings in IND-enabling GLP studies, rapid conversion to TTI-101, and predictable systemic exposures, suggesting improved tolerability and delivery.
• The company possesses deep expertise in STAT3 biology, a highly-validated target within fibrosis-driven diseases.

Negatives

• In the REVERTIPF Phase 2 study, the placebo arm overperformed compared to historical data, and FVC change from baseline overlapped between treatment arms with large variability.
• Treatment-emergent adverse events (TEAEs) in the REVERTIPF study resulted in early discontinuations for 56.7% of patients on TTI-101 400mg/day and 62.1% on TTI-101 800mg/day, compared to 10.3% for placebo.
• The addition of nintedanib (standard of care) to TTI-101 meaningfully increased the incidence of diarrhea in IPF patients (73.5% with TTI-101 + Nintedanib vs. 44.0% with TTI-101 alone).
• The REVERTLiver Cancer interim data for Cohort B (TTI-101 + Pembrolizumab) showed a lower ORR (8%) compared to Cohort A (33%) and Cohort C (33%).

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results or events could differ materially from disclosed plans, intentions, or expectations.
• Risks regarding the business are described in detail in SEC filings, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• Estimates and statistical data relating to market size and growth are subject to a number of assumptions and limitations, and undue weight should not be given to such estimates.
• Projections, assumptions, and estimates of future performance are necessarily subject to a high degree of uncertainty and risk.
• Cross-study comparisons are inherently limited and may suggest misleading similarities and differences, and the values shown may not be directly comparable.

Future Outlook

Tvardi Therapeutics anticipates multiple near-term data catalysts in the first half of 2026, including Phase 1 healthy volunteer data for TTI-109 and topline data from the Phase 1b/2 REVERTLiver Cancer trial for TTI-101 in Hepatocellular Carcinoma. The company expects its current cash and cash equivalents to fund its operating plan into the fourth quarter of 2026.

Management Comments

• Deep expertise in STAT3 biology provides the potential to serve as a disease-modifying therapy.
• TTI-109 is designed to enhance delivery of the STAT3 inhibitor and improve tolerability.
• STAT3 inhibition has demonstrated target engagement and disease modification across animal models of proliferative disease.
• TTI-101 is designed to address the unmet need in proliferative disease.
• REVERTIPF provided additional proof of mechanism for STAT3 inhibition in fibrotic-driven diseases.
• TTI-101 is designed to provide a distinct and synergistic mechanism for unmet need in HCC.

Industry Context

The company operates in the highly competitive biotechnology and pharmaceutical industry, focusing on fibrosis-driven diseases and oncology. Its STAT3 inhibition approach targets a well-recognized pathway in cancer and fibrotic conditions, aiming to address significant unmet medical needs in Idiopathic Pulmonary Fibrosis and Hepatocellular Carcinoma, where current standard-of-care treatments have limitations in efficacy and tolerability.

Comparison to Industry Standards

• In the REVERTIPF Phase 2 study, the placebo arm overperformed compared to historical data (e.g., INPULSIS trials), suggesting variability in IPF clinical trial outcomes.
• TTI-101 monotherapy in the Phase 1 HCC trial demonstrated an Objective Response Rate (ORR) that exceeds the current expected ORR of less than 5% for second-line HCC therapies.
• REVERTLiver Cancer interim Phase 1b/2 data for TTI-101 in combination with atezolizumab/bevacizumab (Cohort C) showed a 50% DCR and 33% ORR, which compares favorably to third-party trials like Tempest (63% DCR, 10% ORR), MORPHEUS (56% DCR, 11% ORR), and IMBrave150 (74% DCR, 27% ORR).
• The company notes that 49% of patients in IMBrave150's atezolizumab/bevacizumab arm had HBV-associated HCC, which demonstrated a higher likelihood of benefit, whereas REVERTLiver Cancer Cohort C had no patients with HBV-associated HCC, potentially making its results more impressive in a broader population.
• The development of Danvatirsen (another STAT3 ASO) in combination with Durvalumab in 2L HNSCC was suspended due to observed adverse events, onerous dosing, and poor pharmacodynamics, highlighting the challenges in STAT3 inhibition and Tvardi's potential differentiation with TTI-101 and TTI-109.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials, especially in HCC, yield positive results and lead to regulatory approvals. Risk of share price volatility based on clinical trial outcomes and future funding needs.
• Patients: Potential for new, effective treatments for Idiopathic Pulmonary Fibrosis and Hepatocellular Carcinoma, addressing unmet medical needs.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline.
• Creditors/Investors: Financial stability supported by current cash runway into Q4 2026, but future capital raises may be necessary for continued development.

Next Steps

• Release of TTI-109 Phase 1 healthy volunteer data in 1H 2026.
• Release of topline data from TTI-101 Phase 1b/2 HCC trial in 1H 2026.
• Continue evaluating TTI-101 in monoand combination therapy in fibrosis-driven HCC Phase 2.
• Continue Phase 1 trial in healthy volunteers for TTI-109 to demonstrate pharmacokinetics, bioequivalence, and tolerability.

Key Dates

Recommendation

The company has presented mixed results for its IPF program, with challenges in the Phase 2 trial, but promising interim data for its HCC program and a new prodrug (TTI-109) with improved characteristics. The upcoming data catalysts in 1H 2026 are significant and could materially impact the stock. Given the current cash runway into Q4 2026, the company has sufficient funds to reach these milestones. A 'hold' recommendation is appropriate as investors await these critical data readouts, which will provide clearer direction on the company's future prospects and valuation.

Keywords

Tvardi Therapeutics, STAT3 inhibitor, TTI-101, TTI-109, Idiopathic Pulmonary Fibrosis, Hepatocellular Carcinoma, IPF, HCC, fibrosis, oncology, clinical trials, biotechnology, pharmaceuticals, drug development